Benitec Biopharma (BNTC)
(Delayed Data from NSDQ)
$8.55 USD
-0.47 (-5.21%)
Updated May 28, 2024 04:00 PM ET
After-Market: $8.60 +0.05 (0.58%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BNTC 8.55 -0.47(-5.21%)
Will BNTC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for BNTC based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for BNTC
CureVac: Remains A Hold Based On Bird Flu Vaccine And Oncology Advancements
Buy Rating for Benitec Biopharma on Promising Early-Stage Clinical Data and Solid Financials
Benitec Biopharma files to sell 32.87M shares of common stock for holders
Benitec Biopharma files to sell 32.87M shares of common stock for holders
FFIE, OGEN and CCLD among mid-day movers